Recruiting
Phase 1

CX11

Sponsor:

Corxel Pharmaceuticals

Code:

NCT07652047

Conditions

Obesity & Overweight

Eligibility Criteria

Sex: Female

Age: 18 - 55

Healthy Volunteers: Not accepted

Interventions

CX11

Placebo

CX11

Study Details

Brief summary:

A multi-center, randomized, placebo-controlled, double-blinded (within cohorts), Sponsor-unblinded, Phase 1b study to explore the safety, pharmacokinetics, and pharmacodynamics of CX11 tablets in participants with obesity or overweight with weight-related comorbidities.

Conditions

Obesity & Overweight

Study ID

NCT07652047

Start date

May 11, 2026

Status verified date

Jun, 2026

Completion date

Jun, 2027

Anticipated

Primary completion date

Mar, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: Female

Age: 18 - 55

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Male or female, 18-55 years.
  • BMI ≥30.0 to ≤39.9 kg/m², or ≥27.0 to <30.0 kg/m² with at least 1 weight-related comorbidity: prediabetes, hypertension, dyslipidemia, or obstructive sleep apnea.
  • Prior unsuccessful diet/exercise weight-loss attempt and stable body weight within 90 days.
  • Able to comply with study procedures and reproductive requirements.

Exclusion Criteria:

  • Diabetes or obesity due to endocrine/genetic causes.
  • Recent weight-loss drugs, GLP-1-based therapy, glucose-lowering drugs, obesity surgery/device, or investigational treatment.
  • Significant cardiovascular, ECG/QT, pancreatic, gallbladder, GI, liver, kidney, thyroid, psychiatric, malignant, infectious, autoimmune, or lab abnormality risks.
  • Personal/family history of medullary thyroid carcinoma or multiple endocrine neoplasia.
  • Pregnancy, breastfeeding, recent nicotine/drug use, excessive alcohol use, or any condition/medication making participation inappropriate.

Study Design

Enrollment

90 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

placebo comparator: Placebo group

Placebo

experimental: CX11 Group A

experimental: CX11 Group B

experimental: CX11 Group C

Interventions

CX11

CX11 tablets administered orally once daily (QD) with meals

Placebo

Matching placebo tablets administered orally once daily (QD) with meals

CX11

CX11 tablets administered orally once daily (QD) with high fat, high calorie meal

Primary outcome measure

  • Percentage change in body weight from baseline [ Time Frame: Week 26 ]

Central Contacts and Locations

Central contacts

Study coordinator

201-268-3723information.center@corxelbio.com

Locations

Corxel Investigational site

Recruiting

Las Vegas, Nevada, United States, 89113

Contacts

Study Director

201-268-3723information.center@corxelbio.com

Corxel Investigational Site

Recruiting

Austin, Texas, United States, 78744

Contacts

Study Director

201-268-3723information.center@corxelbio.com

More Information

Sponsor

Corxel Pharmaceuticals

Last update posted

Jun 17, 2026

Last verified

Jun, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by Corxel Pharmaceuticals on 2026-06-17.